
|Videos|January 8, 2019
Expert Addresses Major Challenge in Treatment of Myeloma
Author(s)David M. Siegel, MD, PhD
David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Advertisement
David S. Siegel, MD, PhD, chief of the division of multiple myeloma at John Theurer Cancer Center, Hackensack Meridian Health, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
According to Siegel, there is a notion that it is imperative to change classes of drugs when there is progression of disease. This is believed by both community oncologists and myeloma experts alike.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































